CEO SUMMARY: For labs currently processing prostate biopsy cases with five or more cores and for those pathologists interpreting those cases, there is a lack of clarity about new Medicare policies. As one example, risk of an audit is significant because of recent guidance issued by one Medicare contractor. Another source of risk for labs …
Lawyer Advises on Risk Of Prostate Biopsy Audits Read More »
To access this post, you must purchase The Dark Report.